China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the first patient enrollment in a regulatory study designed to assess the safety and efficacy of GPN00289. This innovative temperature sensitive embolic product is intended for use in arterial chemoembolization of primary liver cancer.
GPN00289: An Innovative Medical Device for Tumor Treatment
GPN00289 has been certified as an innovative medical device by the China National Medical Products Administration (NMPA). It is a temperature sensitive embolization material used in the treatment of both benign and malignant tumors that are rich in blood vessels. The product’s unique properties allow it to respond to temperature changes, enabling it to transition from a liquid to a solid state. This feature makes GPN00289 highly adaptable for embolizing blood vessels of varying sizes and shapes, which is crucial in the treatment of tumors.
Advancing Treatment Options for Liver Cancer
The initiation of the clinical trial marks a significant step forward in advancing treatment options for patients with primary liver cancer. GPN00289’s ability to provide targeted embolization offers a potentially more effective approach to managing blood supply to tumors, thereby improving patient outcomes.-Fineline Info & Tech
